Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) Patents (Class 424/172.1)
  • Patent number: 10286048
    Abstract: This disclosure relates to materials and methods useful for vaccinating mammals against the effects of envenomation by venomous organisms (including the Western Rattlesnake) by making use of venom from multiple distinct populations, subspecies or species of the organism, to make a vaccine more broadly protective against other populations, subspecies or species. This disclosure also relates to a method for determining which organisms which are capable of envenomation should be pooled for optimizing the coverage and efficacy of a vaccine which is produced from the venoms (or toxoid derivatives) in the combination.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 14, 2019
    Inventors: James G. McCabe, James Brockett, Thomas M. McCabe
  • Patent number: 10287346
    Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 14, 2019
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Motonori Hashimoto, Toshihide Yamashita
  • Patent number: 10241115
    Abstract: The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert H. Pierce, Jennifer H. Yearley, Scott P. Turner, Belma Dogdas, Ansuman Bagchi
  • Patent number: 10213513
    Abstract: This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 26, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10208129
    Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: February 19, 2019
    Assignee: National Research Council of Canada
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes
  • Patent number: 10202463
    Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: February 12, 2019
    Assignee: Thomas Jefferson University
    Inventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
  • Patent number: 10166251
    Abstract: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: January 1, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Mariusz A. Wasik, Qian Zhang
  • Patent number: 10160805
    Abstract: Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: December 25, 2018
    Assignees: New York University, Cornell University
    Inventors: Randy S. Longman, Gretchen E. Diehl, Dan R. Littman
  • Patent number: 10144932
    Abstract: Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein (“Nurr1”). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: December 4, 2018
    Assignee: Board of Trustees of Michigan State University
    Inventors: Fredric P. Manfredsson, Jack W. Lipton, Nicholas Kanaan, Timothy Collier, Kathy Steece-Collier, Caryl E. Sortwell
  • Patent number: 10137195
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 27, 2018
    Assignees: Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • Patent number: 10058543
    Abstract: Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 28, 2018
    Assignee: DALHOUSIE UNIVERSITY
    Inventor: Christopher McMaster
  • Patent number: 10040855
    Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: August 7, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown
  • Patent number: 10035853
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 31, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: William Robert Arathoon, Ishai Padawer, Luis Antonio Cano, Vikram Natwarsinhji Sisodiya, Karthik Narayan Mani, David Liu
  • Patent number: 10035861
    Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: July 31, 2018
    Assignee: Amgen Inc.
    Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
  • Patent number: 10017475
    Abstract: Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of cancer, and in particular cancer presenting as metastatic tumors.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: July 10, 2018
    Assignee: XAVIER UNIVERSITY OF LOUSIANA
    Inventors: Guangdi Wang, Shilong Zheng, Qiu Zhong, Qiang Zhang
  • Patent number: 10004780
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: June 26, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Therese Cronin, Leah Byrne, Ram Fridlich
  • Patent number: 9933439
    Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: April 3, 2018
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Alex Kentsis, Hanno Steen, Richard Bachur
  • Patent number: 9890213
    Abstract: Methods for treating diseases associated with chemokine (C-X-C motif) ligand 13 (CXCL13) expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 13, 2018
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • Patent number: 9834607
    Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 5, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. Kuchroo, Ana C. Anderson
  • Patent number: 9816999
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: November 14, 2017
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Patent number: 9815898
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Patent number: 9771417
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 26, 2017
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky
  • Patent number: 9758594
    Abstract: The present invention relates to a multivalent antibody comprising multiple heavy chain variable regions of antibody linked to each other via a linker comprising an amino acid sequence encoding an immunoglobulin domain or a fragment thereof.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 12, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventor: Nobuaki Takahashi
  • Patent number: 9708590
    Abstract: The present invention provides the three-dimensional structure of human ?-N-acetylglucosaminidase (NAGLU) protein. This crystallographic information is useful in the identification and development of novel binding compounds of NAGLU, NAGLU mutants, for example, those associated with Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)), and other NAGLU family members (family 89 ?-N-acetylglucosaminidase) which may modulate the activity and/or stability of mutated NAGLU. Such compounds may be useful for the treatment of Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 18, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Muthuraman Meiyappan, Michael F. Concino, Angela W. Norton
  • Patent number: 9709563
    Abstract: Passivated substrates are provided for use in assays, comprising at least one covalently bonded ligand having specific binding activity for a molecule, and at least one covalently bonded blocking agent, wherein said ligand is directly bonded to the substrate surface. In certain embodiments, the ligand and blocking agent are covalently bonded only to the substrate surface, and not directly bonded to each other. In certain other embodiments, the ligand and blocking agent have at least one additional covalent bond to one another. Methods for preparing and using passivated substrates in bioassays are also provided.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 18, 2017
    Assignee: Agilent Technologies, Inc.
    Inventor: Roderick Nicholas Hobbs
  • Patent number: 9688747
    Abstract: The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 27, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 9683040
    Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: June 20, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
  • Patent number: 9623115
    Abstract: Disclosed herein are compositions and methods of use of dock and lock (DNL) complexes comprising a first antibody or fragment that binds to a stem cell antigen and a second antibody or fragment thereof that binds to an antigen on a diseased or damaged tissue or organ. The DNL complexes are of use for targeting stem cells to diseased or damaged organs or tissues and may be used to treat a variety of diseases or conditions that are responsive to stem cell therapy.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 18, 2017
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 9598733
    Abstract: Seven protective alleles for IgA nephropathy have been discovered that can be identified by analyzing a DNA sample for seven respective SNPs. A method is provided for identifying and treating subjects at risk of developing IgA neuropathy based on a new seven-SNP genetic risk score. Also provided are screening methods to identify compounds that bind to and reduce the expression or biological activity of a either CFHR1 or CFHR3.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 21, 2017
    Assignees: The Trustees of Columbia University in the City of New York, Yale University
    Inventors: Ali Gharvari, Krzysztof Kiryluk, Richard Lifton
  • Patent number: 9587032
    Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: March 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz
  • Patent number: 9574005
    Abstract: Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: February 21, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Masaya Yasutake
  • Patent number: 9561290
    Abstract: The invention relates to new functionalized thieno-indole derivatives of formula (I) or (II) which have cytotoxic activity and are useful in treating diseases such as cancer and cellular proliferation disorders. The invention also relates to the use of these functionalized thieno-indole derivatives in the preparation of conjugates.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: February 7, 2017
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Italo Beria, Michele Caruso, Vittoria Lupi, Paolo Orsini, Matteo Salsa
  • Patent number: 9562087
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: February 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Patent number: 9546206
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 17, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Patent number: 9486469
    Abstract: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: November 8, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Mariusz A. Wasik, Qian Zhang
  • Patent number: 9393268
    Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 19, 2016
    Assignee: Thomas Jefferson University
    Inventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
  • Patent number: 9353188
    Abstract: Disclosed herein are novel compositions and methods for the inhibition of Plexin B2-mediated Angiogenin activity. Such compositions and methods are useful, for example, for the treatment of cancer, the treatment of wet AMD and the inhibition of angiogenesis. Also disclosed herein are methods of determining whether a test agent is a modulator of Plexin B2 activity.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: May 31, 2016
    Assignees: President and Fellows of Harvard College, Tufts Medical Center, Inc.
    Inventors: Guofu Hu, Wenhao Yu
  • Patent number: 9339526
    Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: May 17, 2016
    Assignee: UNIVERSITY OF MANITOBA
    Inventors: Aaron Marshall, Sen Hou
  • Patent number: 9250250
    Abstract: The invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to LGI1. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to LGI1 and treating a tumor associated with the disease.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: February 2, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Josep Dalmau
  • Patent number: 9248181
    Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: February 2, 2016
    Assignee: Merus B.V.
    Inventors: Cornelis A. De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
  • Patent number: 9102732
    Abstract: Disclosed are immunological compositions and methods for reducing activity of glucagon signaling using antibodies against glucagon receptor.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: August 11, 2015
    Assignee: NEOPHARM CO., LTD.
    Inventors: Eunkyung Lee, Seong-Kyung Seo, Tae-Seong Kim
  • Patent number: 9080149
    Abstract: The present invention provides the use of the cell surface antigen CD51 as a negative selection marker for neuronal cells and a method for enrichment, isolation and/or detection of neuronal cells comprising the steps a) contacting a sample containing neuronal cells with an antigen-binding fragment specific for the CD51 antigen coupled to a solid phase, thereby labeling the CD51 positive cells of said sample and b) isolating the non-labeled cells of said sample.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: July 14, 2015
    Assignee: Miltenyi Biotec GmbH
    Inventors: Andreas Bosio, Melanie Jungblut
  • Patent number: 9080183
    Abstract: The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5? shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: July 14, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Christian Klein, Erhard Kopetzki
  • Patent number: 9078879
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • Patent number: 9075045
    Abstract: An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: July 7, 2015
    Assignees: The Commonwealth Medical College, University of Florida Research Foundation, Inc.
    Inventors: David Alan Zacharias, Sonia Lobo Planey
  • Publication number: 20150147343
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: July 2, 2014
    Publication date: May 28, 2015
    Applicant: University of Zurich
    Inventors: Roger NITSCH, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Publication number: 20150147322
    Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.
    Type: Application
    Filed: February 9, 2015
    Publication date: May 28, 2015
    Inventors: Gino Luigi VAIRO, Andrew NASH, Eugene MARASKOVSKY, Nick WILSON, Samantha BUSFIELD, Con PANOUSIS
  • Publication number: 20150140014
    Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 21, 2015
    Applicant: Samsung Electronics Co., Ltd.
    Inventors: Seung Hyun LEE, Geun Woong Kim, Kyung Ah Kim, Hye Won Park, Ho Yeong Song, Young Mi Oh, Saet Byoul Lee, Ji Min Lee, Kwang Ho Cheong, Yun Ju Jeong, Mi Young Cho, Jae Hyun Choi, Yun Jeong Song, Yoon Aa Choi
  • Publication number: 20150140016
    Abstract: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods for treating multiple myeloma, for restoring osteoprotegerin (OPG) expression in a cell, for inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) expression in a cell, and for increasing bone mass in a subject. These methods utilize a DKK1 neutralizing antibody, an anti-sense oligonucleotide against a DKK1 gene, or a shRNA against a DKK1 gene to inhibit the activity of the DKK1 protein.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: John D. Shaughnessy, JR., Bart Barlogie, Ya-Wei Qiang
  • Publication number: 20150140009
    Abstract: The invention provides methods for the treatment of radiation exposure featuring agents that interfere with the expression, production, release, accumulation, or activity of a TNF?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES receptor; or a TNF-?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES peptide or fragment thereof.
    Type: Application
    Filed: August 19, 2014
    Publication date: May 21, 2015
    Inventor: David A. Goukassian